Search results
CVS COVID-19 Vaccine Near Columbus OH
www.cvs.comPharmacy LocationBy appointment only3307 East Broad Street(614) 235-8605109 South High Street Suite 100(614) 224-4261759 Neil Avenue(614) 224-92751515 West Broad Street(614) 274-16202100 East Dublin Granville Road(614) 891-14101495 West 5th Avenue(614) 486-71592160 North High Street(614) 294-2105Feb 1, 2024 · New data from CDC show that the updated COVID-19 vaccines were effective against COVID-19 during September 2023 – January 2024, including against variants from the XBB lineage, which is included in the updated vaccine, and JN.1, a new variant that has become dominant in recent weeks. The virus that causes COVID-19 will continue to evolve.
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against ...
In a multistate network of U.S. hospitals during...
- Sustained Effectiveness of Pfizer-BioNTech and Moderna ...
Vaccine effectiveness was 86% 2–12 weeks after vaccination...
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against ...
3 days ago · 2023-2024 Pfizer-BioNTech COVID-19 vaccine. In December 2020, the Pfizer-BioNTech COVID-19 vaccine two-dose series was found to be both safe and effective in preventing COVID-19 infection in people age 18 and older. This data helped predict how well the vaccines would work for younger people. The effectiveness varied by age.
- Overview
- Discussion
- References
On April 28, 2021, this report was posted online as an MMWR Early Release.
Altmetric:
Citations:
Views:
Views equals page views plus PDF downloads
Figure
Monitoring the effectiveness of SARS-CoV-2 vaccination under routine public health use and specifically against severe outcomes in patients at higher risk, including older adults, is a high priority. In this multistate analysis of adults aged ≥65 years, receipt of an authorized COVID-19 vaccine was associated with significant protection against COVID-19 hospitalization. Effectiveness was 94% among adults who were fully vaccinated and 64% among adults who were partially vaccinated (i.e., onset of COVID-like illness ≥14 days after the first vaccine dose in a 2-dose series but <14 days after the second dose). These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). Early reports from Israel have also documented the real-world effectiveness of SARS-CoV-2 vaccination, including among older adults (7,9). However, those postmarketing reports only represented the Pfizer-BioNTech vaccine. In the current report, Pfizer-BioNTech and Moderna vaccine products were equally represented, and approximately one half of the patients were aged ≥75 years, providing evidence of real-world effectiveness of both vaccines against an important measure of severe COVID-19 in older adults. Moreover, in assessing the impact of receiving only a single dose, no significant vaccine effectiveness <14 days after the first dose of a SARS-CoV-2 vaccine was detected. This suggests that bias is unlikely in the primary estimates of vaccine effectiveness from partial and full vaccination. This also highlights the continued risk for severe illness shortly after vaccination, before a protective immune response has been achieved and reinforces the need for vaccinated adults to continue physical distancing and prevention behaviors, such as use of face masks and recommended hand hygiene at least 14 days after the second dose of a 2-dose vaccine. The findings suggest that SARS-CoV-2 vaccines can reduce the risk for COVID-19–associated hospitalization and, as a consequence of preventing severe COVID-19, vaccination might have an impact on post-COVID conditions (e.g., “long COVID”) and deaths (2,10).
The findings in this report are subject to at least six limitations. First, the CIs for VE estimates were wide because of the small sample size, and the number of participants was too small to assess VE by vaccine product, age group, or underlying conditions. Second, as an interim analysis that included self-reported data, vaccination status might have been misclassified, or participants might have had imperfect recollection of vaccination or illness onset dates. Third, selection bias and residual confounding cannot be excluded. Fourth, although the analysis included hospitalized adults from 14 states, the participants were not geographically representative of the U.S. population. Fifth, the case-control design infers protection based on associations between disease outcome and previous vaccination but cannot establish causation. Finally, duration of VE and VE for nonhospitalized COVID-19 was not assessed.
1.Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–64. https://doi.org/10.15585/mmwr.mm6915e3external icon PMID:32298251external icon
2.Wortham JM, Lee JT, Althomsons S, et al. Characteristics of persons who died with COVID-19—United States, February 12–May 18, 2020. MMWR Morb Mortal Wkly Rep 2020;69:923–9. https://doi.org/10.15585/mmwr.mm6928e1external icon PMID:32673298external icon
3.Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep 2021;69:1657–60. https://doi.org/10.15585/mmwr.mm695152e2external icon PMID:33382671external icon
4.Baden LR, El Sahly HM, Essink B, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. https://doi.org/10.1056/NEJMoa2035389external icon PMID:33378609external icon
5.Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577external icon PMID:33301246external icon
6.Patel MM, Jackson ML, Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA 2020;324:1939–40. https://doi.org/10.1001/jama.2020.19328external icon PMID:33064144external icon
- Mark W. Tenforde, Samantha M. Olson, Wesley H. Self, H. Keipp Talbot, Christopher J. Lindsell, Jay S...
- 2021
The Pfizer and Moderna vaccines are strongly recommended as safe and effective at preventing serious illness or death from COVID-19. From December 2020 to December 2021, about 470 million doses of COVID-19 vaccine have been given in the U.S.
News about COVID-19, vaccines, AstraZeneca
News about Moderna, GSK, vaccines
Also in the news
Oct 21, 2021 · Effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% (95% CI = 83%–97%), during the period when B.1.617.2 (Delta) was the predominant variant.
Dec 30, 2021 · Pfizer-BioNTech reported 95% efficacy (CI: 90.3%–97.6%) for their vaccine, with low serious adverse event rates in both the vaccinated and control groups ( Polack et al., 2020 ). The vaccine was initially FDA-approved for ages 16 and over, requiring two doses at a recommended interval of 21 days.
Aug 18, 2022 · The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection. What is the recommended dosage? For all persons aged 12 years and above, SAGE recommends two doses (30 µg, 0.3 ml each), 4-8 weeks apart given intramuscularly into the deltoid muscle.
